资讯

Endothelin-1 is a small vasoconstrictor peptide that was first identified in 1988. Here we review the evidence implicating ET-1 in tumorigenesis. In particular, we concentrate on the role of ET-1 ...
Septerna is developing SEP-786, a novel, potent and selective oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist for the treatment of patients with hypoparathyroidism, a rare ...
Biolexis Therapeutics’ small molecule BLX-7006 reduced the weight of obese mice by 15% over a 28-day span. | Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss.
N-butanol, also known as 1-butanol or n-butyl alcohol, is a key organic chemical used in the production of various products including paints, adhesives and plasticizers. Related Stories.
Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13. November 30, 2023 08:00 AM Eastern Standard Time. BELLEVUE, Wash. & SAN DIEGO-- ...
Dreams will end live support on September 1 as Media Molecule shifts its focus to “an exciting new project,” the developer announced.. Players will still be able to play, create, and share ...
Dublin, July 19, 2023 (GLOBE NEWSWIRE) -- The "N-Butanol Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Grade (Industrial Grade v/s Pharmaceutical ...
N-Butanol Market, By Application (Butyl Acrylate, Butyl Acetate, Glycol Ethers, Direct Solvents, Plasticizers), By End-Use industry (Agriculture, Building & Construction, Paints & Coatings, Marine ...
China said on Friday it will retain anti-dumping duties on n-butanol imports originating in Taiwan, Malaysia and U.S. for a period of five years from Dec 29.
Yunovia Co. Ltd. gained clearance in South Korea to start a multiple ascending dose phase I study for ID-110521156 – a novel, orally available, small-molecule, glucagon-like peptide-1 (GLP-1) agonist.
Askgene cleared to enter clinic with anti-PD-1/IL-15 prodrug fusion molecule ASKG-915. Jan. 3, 2023. Askgene Pharma Inc. has received FDA clearance of its IND application to start a phase I study of ...
Roche reported its oral GLP-1 agonist led to an average 6.1% weight loss at four weeks, according to preliminary results from part of a Phase 1 study. The small molecule comes from Roche’s $2.7 ...